Mark A. Dickson

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

49h-index11.6kcitations386works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(143), Cancer Immunotherapy and Biomarkers(89), Advanced Breast Cancer Therapies(83), CAR-T cell therapy research(36), Vascular Tumors and Angiosarcomas(36)

Publications386 total

Data from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Figure S2 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Table S1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Figure 2 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Table S2 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Table S3 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Figure 3 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Table S4 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Figure S1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Table 1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Figure 1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Table 2 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Figure S3 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Table S5 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcome in Sarcoma
Clinical Cancer Research·2026
A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors
Future Oncology·2025Open Access
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Cancer Research Communications·2025Open Access
Supplementary Data 3 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
2025Open Access
Supplementary Data 1 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
2025Open Access
Supplementary Data 2 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
2025Open Access
page 1 of 20Next →

Frequent Co-authors

Gary K. Schwartz(21), William D. Tap(21), Sandra P. D’Angelo(20), Mary Louise Keohan(16), Mrinal M. Gounder(16), Cristina R. Antonescu(16), Samuel Singer(14), Aimeé M. Crago(11), Li‐Xuan Qin(10), Ping Chi(10), Richard D. Carvajal(9), Ciara M. Kelly(7), Joseph P. Erinjeri(6), Andrew Koff(6), Narasimhan P. Agaram(6), Robert G. Maki(6), Jedd D. Wolchok(5), Sujana Movva(5), Andrew J. Wagner(5), Margaret K. Callahan(4)